Theseus Pharmaceuticals Inc
(NAS:THRX)
$
4.06
0 (0%)
Market Cap: 181.28 Mil
Enterprise Value: -20.19 Mil
PE Ratio: 0
PB Ratio: 0
GF Score: 24/100 Theseus Pharmaceuticals Inc at Stifel Targeted Oncology Days (Virtual) Transcript
Apr 26, 2023 / 04:00PM GMT
Release Date Price:
$10.6
(+9.05%)
Brad Canino
Stifel Financial Corp. - Analyst
Thanks, everyone, for continuing to join us on our inaugural Stifel Target Oncology Days. How many have as Brad Canino, senior analyst here at Stifel, and I'm delighted to be joined by Tim Clackson, the CEO of Theseus, to sit down with me for a about 25-minute fireside chat. So thank you so much, Tim, for joining us.
Tim Clackson
Theseus Pharmaceuticals, Inc. - President & CEO
Thanks, Brad, for the opportunity.
Questions & Answers
Brad Canino
Stifel Financial Corp. - Analyst
Cool. Now I think we'll open with a company question but somewhat of a specific question, because I'd love you to just talk about your PRA tool that you use, define it; and why it's important for mutant protein targets, particularly for the drugs in targeted cancers in your pipeline?
Tim Clackson
Theseus Pharmaceuticals, Inc. - President & CEO
Of course. Happy to do that. So PRA stand so the Predictive Resistance Assay. Why are we
Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot